{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bites-human-animal/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"7398d7dd-8a7d-5695-b963-bba32a0445a8","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field fb59c418-171a-433e-82a8-a877009b42bb --><h2>Doxycycline</h2><!-- end field fb59c418-171a-433e-82a8-a877009b42bb -->","summary":"","htmlStringContent":"<!-- begin item 20c37f39-1f00-46a6-a401-a877009b4054 --><!-- end item 20c37f39-1f00-46a6-a401-a877009b4054 -->","topic":{"id":"66885481-1c78-50d7-bd40-cee6daf3a22b","topicId":"1f9ba5f4-d4ca-402b-857f-1ef0227e6eaa","topicName":"Bites - human and animal","slug":"bites-human-animal","lastRevised":"Last revised in October 2020","chapters":[{"id":"4d7c4615-e565-58f7-ab3f-9af67d5fa066","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d9aea4af-b77b-548e-a62d-b1b69d689e70","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b16f539f-9832-520a-b08e-b9870416e2ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"814b9650-9309-581c-ad8b-77bd0f59d573","slug":"changes","fullItemName":"Changes"},{"id":"451e8923-57cf-55b9-88b6-7767cf1870b3","slug":"update","fullItemName":"Update"}]},{"id":"4f4d63cd-fedc-53a6-9963-001d4f253f2c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8bb57dc0-b6ce-5ebb-a31d-25b2d527ed6c","slug":"goals","fullItemName":"Goals"},{"id":"51f172a3-e955-5bda-98c3-61a0bd719f16","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"150a707d-3a0a-5115-b633-9ab844daab23","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"77f07ad2-c9ad-5bc2-9b81-5c305f9e8ca3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"51c4f343-6ac9-549d-a068-43084108f8c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"909ff9e5-d816-5a1a-a545-0b5d010352f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"601e2fbe-0e18-597e-9476-633c9f4ef7b3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5c3cdd6-9531-5a6c-b1bc-a6e8d12b2307","slug":"definition","fullItemName":"Definition"},{"id":"2158dea0-437f-5805-9e65-e1c277e52475","slug":"characteristics-of-different-types-of-bites","fullItemName":"Characteristics of different types of bites"},{"id":"dcc5a332-7954-5ea2-88e1-7093a2c27960","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d2e33eaa-035d-54f9-b1e6-ee9d3c605297","slug":"complications","fullItemName":"Complications"},{"id":"f9c4fd96-ca8a-53ba-bb96-fe24ea11c8be","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"27cd943b-33a7-5304-8c4f-0f2da1c77fb9","fullItemName":"Management","slug":"management","subChapters":[{"id":"4a38ec65-3aac-5dff-b0e6-ce328b564e2d","slug":"managing-a-human-bite","fullItemName":"Scenario: Managing a human bite"},{"id":"3998b5bd-33dc-52ed-848d-b1c3b6d01573","slug":"managing-a-cat-or-dog-bite","fullItemName":"Scenario: Managing a cat or dog bite"}]},{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a0c8184c-9c4d-5943-9d34-6471f2fe8744","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"0e041b11-cf29-519b-99be-1751ece6b17e","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"7398d7dd-8a7d-5695-b963-bba32a0445a8","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"696d5b30-ff2f-5b72-875c-03cf5db390c0","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"6410092b-90ae-58a9-8065-103199eca1cb","slug":"paracetamol-ibuprofen","fullItemName":"Paracetamol and ibuprofen"}]},{"id":"703fd48e-b059-5fac-8aef-986c90ceca15","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"869edd83-cb34-55d6-9d47-6931a23adf4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e9f1883-896e-54dd-8156-ae8a2aa744d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3edab9d3-1d3a-5e9d-b8df-83d2ffc14bf0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e969da1-bdae-5ba7-9471-72cff35d2dac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8d0ba91-234c-5494-a990-bbe559b68c05","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2e4ab4-ad2f-5ad9-a9c6-3d59693be83c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bdc0f3ee-0644-5a81-b04b-3f1ae3e4310b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"7ef5bb40-bb31-5d4e-95f5-26f00cfe0ee9","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field a44c935c-143b-4afd-9bba-a877009d3066 --><h3>What dosage of doxycycline should I prescribe?</h3><!-- end field a44c935c-143b-4afd-9bba-a877009d3066 -->","summary":"","htmlStringContent":"<!-- begin item d5d5f1ed-b5eb-49cb-ad2f-a877009d2e3d --><!-- begin field 10633513-afb7-4bdb-9a94-a877009d3066 --><ul><li>For treatment of an infected bite wound, the dosage of oral doxycycline is:<ul><li>Adults and young people aged 12–17 years: 200 mg on the first day and then 100 mg or 200 mg daily for 5 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">NICE, 2020</a>].</li><li>Child: doxycycline is contraindicated (and not licensed) in children less than 12 years of age because of the risk of dental staining and hypoplasia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>].</li></ul></li><li>For prophylaxis the dosage is as described above and prescribed for 3 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">NICE, 2020</a>].</li></ul><!-- end field 10633513-afb7-4bdb-9a94-a877009d3066 --><!-- end item d5d5f1ed-b5eb-49cb-ad2f-a877009d2e3d -->","subChapters":[]},{"id":"8fe31126-24b4-5efd-9df4-f075dfaad0f1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e4fa0c91-418e-42ff-868a-a877009d8c86 --><h3>What are the contraindications and cautions when prescribing doxycycline?</h3><!-- end field e4fa0c91-418e-42ff-868a-a877009d8c86 -->","summary":"","htmlStringContent":"<!-- begin item c87b8a5a-620e-41fe-ae5a-a877009d8997 --><!-- begin field 701ed757-b7f7-43c6-b90a-a877009d8c86 --><ul><li><strong>Do not prescribe doxycycline in:</strong><ul><li>Women who are pregnant or breastfeeding, and children younger than 12 years of age.<ul><li>Tetracyclines are deposited in growing bone and teeth which can result in discolouration of teeth and occasionally dental hypoplasia.</li></ul></li></ul></li><li><strong>Prescribe doxycycline with caution in people with:</strong><ul><li>Hepatic impairment and those receiving potentially hepatotoxic drugs.</li><li>Myasthenia gravis — tetracyclines may increase muscle weakness in people with myasthenia gravis.</li><li>Systemic lupus erythematosus (SLE) — tetracyclines may exacerbate SLE symptoms.</li><li>Renal impairment — avoid excessive doses.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>]</p><!-- end field 701ed757-b7f7-43c6-b90a-a877009d8c86 --><!-- end item c87b8a5a-620e-41fe-ae5a-a877009d8997 -->","subChapters":[]},{"id":"f94023b7-c831-5358-a55e-ac49e3221e76","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8e0bef94-17d4-471e-a15e-a877009daf26 --><h3>What are the adverse effects of doxycycline?</h3><!-- end field 8e0bef94-17d4-471e-a15e-a877009daf26 -->","summary":"","htmlStringContent":"<!-- begin item 5393ae74-2b67-4de8-8990-a877009dac4f --><!-- begin field 949d2f9b-3b1a-479a-bddd-a877009daf26 --><ul><li><strong>Blood disorders</strong> — haemolytic anaemia, thrombocytopenia, neutropenia, eosinophilia (frequency unknown).</li><li><strong>Gastrointestinal</strong> — nausea, vomiting (common), dyspepsia (uncommon). Abdominal discomfort, diarrhoea, tooth discolouration, and enamel hypoplasia in children (frequency unknown).<ul><li><strong>Rarely:</strong> dysphagia, oesophagitis, oesophageal irritation, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hepatic disorders</strong> – hepatotoxicity, hepatitis, jaundice, hepatic failure (frequency unknown).</li><li><strong>Renal disorders</strong> — blood urea increased.</li><li><strong>Skin</strong> — photosensitivity, rash (common).<ul><li><strong>Rarely</strong>: toxic epidermal necrolysis, Stevens–Johnson syndrome, angioedema, erythema multiforme, exfoliative dermatitis, drug reaction with eosinophilia and systemic symptoms (DRESS).</li></ul></li><li><strong>Other rare adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Arthralgia, myalgia.</li><li>Bulging fontanelles in infants.</li><li>Flushing.</li><li>Severe headache and/or visual disturbances — may be an early symptom of benign intracranial hypertension, a rare but serious adverse effect.</li><li>Tinnitus.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>]</p><!-- end field 949d2f9b-3b1a-479a-bddd-a877009daf26 --><!-- end item 5393ae74-2b67-4de8-8990-a877009dac4f -->","subChapters":[]},{"id":"93afb41f-2751-589a-a7e3-7b6dc71b9029","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 35a84ff1-7974-46ae-9dfe-a877009dd86c --><h3>What drug interactions are associated with doxycycline?</h3><!-- end field 35a84ff1-7974-46ae-9dfe-a877009dd86c -->","summary":"","htmlStringContent":"<!-- begin item 37a32141-9a4f-4d14-8b8d-a877009dd550 --><!-- begin field 3c78c76c-a894-4d5e-9438-a877009dd86c --><ul><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc </strong>— these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Avoid taking antacids and other medications containing iron or zinc, 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>CYP3A enzyme inducers</strong> (phenobarbital, carbamazepine or phenytoin) — these may reduce the serum half-life of doxycycline. Monitor and adjust the dose if necessary.</li><li><strong>Insulin </strong>— the blood-glucose lowering effect may be increased if taken with doxycycline. Monitor blood-glucose levels.</li><li><strong>Lithium</strong> — levels may be increased by doxycycline. Consider increasing the frequency of lithium monitoring.</li><li><strong>Methotrexate</strong> — levels may be increased by doxycycline.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of doxycycline.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Retinoids </strong>— there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li><strong>Rifampicin</strong> — doxycycline levels are markedly reduced, which may lead to treatment failure. Monitor the effects and increase doxycycline dose if necessary.</li><li><strong>Warfarin </strong>— the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect. However, there is little evidence to suggest clinical relevance.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">FSRH, 2017</a>]</p><!-- end field 3c78c76c-a894-4d5e-9438-a877009dd86c --><!-- end item 37a32141-9a4f-4d14-8b8d-a877009dd550 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}